

## Neurolix Enters Strategic Collaboration with Jagiellonian University, Kraków, to Explore New Generation of CNS Therapeutics

**Dana Point, 09 January, 2015** -- Neurolix today announced that it had entered into a strategic drug discovery collaboration with Jagiellonian University Medical College in Kraków, Poland. The collaboration will take advantage of resources and technology from both groups to deliver the next generation of central nervous system (CNS) therapeutics targeting disorders such as depression and schizophrenia.

Dr. Adrian-Newman Tancredi, Chief Scientific Officer of Neurolix, commented: "We are delighted to initiate this collaboration with the research team at Jagiellonian University Medical College. By combining the expertise of both groups, we believe this collaboration will provide novel drug treatments to address unmet disorders of the CNS."

Assoc. Prof. Anna Wesołowska, Vice-Dean of Pharmacy Faculty for Research and International Co-operation, added: "The Pharmacy Faculty of Jagiellonian University Medical College has expertise in organic chemistry and CNS pharmacology and Neurolix is a rapidly-expanding bioscience company. We believe that this combination forms an excellent basis for a successful drug discovery partnership in the areas of mood disorders and psychoses."

Depression, anxiety and psychotic disorders such as schizophrenia affect 100 million people in the European Union each year with estimated medical and social costs of over 200 billion €. Many patients do not respond adequately to existing antidepressants and antipsychotics, so a large medical need exists for more efficacious and well tolerated treatments.

### **About Neurolix, Inc.**

Neurolix, located in Dana Point, California, is a privately held biotechnology company developing therapies for disorders of the central nervous system. The Company is focused on developing small molecule drugs for the treatment of neurological disorders such as Parkinson's disease and Rett syndrome and of psychiatric disorders such as depression and schizophrenia. Additional information is available at <http://www.neurolix.com>.

### **About Jagiellonian University, Kraków**

Jagiellonian University in Kraków was positioned by QS World University Rankings as the best Polish university among the world's top 500. It is one of the oldest universities in the world (founded in 1364) and is highly reputed in the fields of medicine and biomedical research. Additional information regarding Jagiellonian University is available at [http://www.uj.edu.pl/en\\_GB/universytet](http://www.uj.edu.pl/en_GB/universytet).

### **Forward Looking Statement**

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including: our dependence on third parties for the development, regulatory approval and successful commercialization of our products, the inherent risk of failure in developing product candidates based on new technologies, risks associated with the costs of clinical development efforts, as well as other risks. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. Neurolix disclaims any intent or obligation to update these forward-looking statements.

### **PRESS CONTACTS**

Dr Mark Varney, CEO Neurolix,  
[mvarney@neurolix.com](mailto:mvarney@neurolix.com)  
(949) 214-4017